Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| J2A-MC-GZPQ | Other Identifier | Eli Lilly and Company |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Orforglipron | Experimental | Participants will receive orforglipron orally |
|
| Placebo | Placebo Comparator | Participants will receive placebo orally |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Orforglipron | Drug | Administered orally |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change from Baseline in Visceral Adipose Tissue (VAT) | Baseline, Week 36 |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change from Baseline in Energy Intake | Baseline, Week 36 | |
| Percent Change from Baseline in Appetite | Baseline, Week 36 | |
| Percent Change from Baseline in Body Weight |
Not provided
Inclusion Criteria:
Have a Body Mass Index (BMI)
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 : Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Pharmacology of Miami | Miami | Florida | 33172 | United States | ||
| Axis |
Not provided
| Label | URL |
|---|---|
| A Study of Orforglipron (LY3502970) in Adult Participants with Obesity or Overweight | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D050177 | Overweight |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
| ID | Term |
|---|---|
| C000729680 | orforglipron |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Administered orally |
|
| Baseline, Week 36 |
| Percent Change from Baseline in Fasting Total Cholesterol | Baseline, Week 36 |
| Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hs-CRP) | Baseline, Week 36 |
| Change from Baseline in International Physical Activity Questionnaire-Long Form (IPAQ-L) Scores | Baseline, Week 36 |
| Dilworth |
| Minnesota |
| 56529 |
| United States |
| Ohio Clinical Trials | Columbus | Ohio | 43212 | United States |
| Endeavor Clinical Trials | San Antonio | Texas | 78240 | United States |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |